RG 4929

Drug Profile

RG 4929

Alternative Names: 11 Beta HSD inhibitor; R4929; RG4929; RO 5093151

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Roche
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glaucoma; Ocular hypertension
  • Discontinued Non-alcoholic fatty liver disease; Type 2 diabetes mellitus

Most Recent Events

  • 31 Jul 2016 Roche completes a phase I trial in Glaucoma and Ocular hypertension USA and Singapore (Ophthalmic, Liquid) (NCT02622334)
  • 01 Nov 2015 Phase-I clinical trials in Glaucoma and Ocular hypertension in USA (Ophthalmic) (NCT02622334)
  • 16 Oct 2012 Discontinued - Phase-I for Non-alcoholic fatty liver disease in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top